CMTA Legacy Society

Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.


WELCOME! Thank you for your interest in Project Foresee.

Project Foresee is a CMTA sponsored project to advance the most promising CMT4C Gene Therapy cure through known steps to ultimately cure the first handful of patients in the next 3 years.

Brief History of CMT4C Gene Therapy research and promising results:

Initial CMTA backed research on a CMT4C Gene Therapy solution dates back to 2018, with the first research papers published in March of 2019 (see Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy). With the promising results from the initial research, Dr. Kleopa and team continued their research with a number of other world-leading scientists, with some incredible results provided in an update on November 1, 2023 (see AAV9-mediated SH3TC2 gene replacement therapy targeted to Schwann cells for the treatment of CMT4C). The results from this research provide the level of confidence needed by the best scientists, neurologists, and researchers in the world to move forward on a dedicated project to treat and hopefully cure the first handful of patients with CMT4C.

Project Foresee

Spearheaded by the Paulsen family in partnership with CMTA, Project Foresee brings together the world’s best experts to advance the most promising cure for CMT4C that exists today. We expect that this project will pave the way to cure dozens, then hundreds, then thousands and possibly millions of patients with CMT.

The core project team includes:

Dr. Sue Bruhn: Chief Executive Officer of Charcot-Marie-Tooth Association (CMTA)
Dr. Kleopas Kleopa: World-renowned CMT4C Scientist who uncovered the gene therapy cure
Dr. Steven Gray: Leading researcher and neurologist Principal Investigator and Project lead for Project Foresee
Bob Paulsen: Serial Entrepreneur & proud parent of Quinn (teenager with CMT4C).

Founding 4C Family Sponsors

The Paulsen Family
The Vorpahl Family
The Monique Manzella and JP Ross Family

Project Foresee will be executed over a 3-year timeframe as funding goals are achieved. We have already progressed through the first few milestones, including a positive response from the FDA to continue our plans as designed. Having this major hurdle in our rearview mirror clears our path as we progress through Toxicology studies to the ultimate step of treating patients. Total project investment is expected to be around $6M.

Learn more about Project Foresee via the Foresee Gala project team presentations.

If you prefer to donate via check, Donor Advised Fund grant, or other, please communicate that your donation is to be directed to “Project Foresee.” Checks can be mailed to:
Charcot-Marie-Tooth Association
PO Box 105
Glenolden, PA 19036

The Charcot-Marie-Tooth Association (CMTA) is a registered 501(c)(3) nonprofit organization. Your donation is tax-deductible to the fullest extent allowed by law. Tax ID: 22-2480896.

Thank you for supporting CMTA!

Thank you again for your interest in learning about and for supporting Project Foresee. Together, we WILL change the world.

Page Last Updated: November 13, 2024